An investigational long-acting amylin analogue studied in receptor-pharmacology and metabolic-signalling research. It is supplied as a lyophilised research material.
Investigational research material
This is not an approved medicinal product. This material is not for human or veterinary use, consumption or administration, and is not intended to diagnose, treat, cure or prevent any disease.
Compound overview
CompoundC
Development codesAM833 / NNC0174-0833
Research classLong-acting acylated amylin analogue
Reference molecular massApproximately 4,409 Da
FormLyophilised material
Research context
Published research describes this as a lipidated, long-acting amylin analogue with activity across amylin and calcitonin receptor-family systems. It has been investigated in receptor-pharmacology, pharmacokinetic and metabolic-signalling studies, both alone and in combination research. References to published studies describe the compound and experimental conditions used by those authors; they do not establish the identity, performance or suitability of any material sold on this page.
Batch documentation
Independent analytical documentation is published where available for specific batches and variations. A result indicator appears only when a published record is available. Match the vial size and batch identifier to the corresponding report before relying on any result.
View available C-Series lab results →
Supply and laboratory handling
- Supplied in the vial size selected above.
- Keep the sealed lyophilised vial dry and protected from direct light.
- A cool, dry place, refrigerator or freezer may be used according to the intended storage duration, compound-specific information and your laboratory’s validated procedure.
- Use clean laboratory technique and equipment appropriate to the intended analytical method.
- Follow the lot-specific documentation and your laboratory’s validated handling and storage procedures.
- Avoid repeated temperature cycling and unnecessary exposure to moisture.
Where a batch document or supplier specification gives different instructions, the lot-specific document takes precedence.
Frequently asked questions
What is C-Series?
Known by the development codes AM833 and NNC0174-0833, it is an investigational long-acting amylin analogue described in published pharmacology and clinical research.
Is C-Series an approved medicine?
No. It remains investigational and this material is supplied solely for controlled laboratory research. It is not supplied as a medicine, treatment, supplement or consumer product.
Which vial sizes are available?
Current vial sizes, stock, pre-order status, pricing and any batch-documentation indicators are shown in the variation selector above.
Does every vial size have a published laboratory result?
No. Results are available only for the selected batches and vial sizes marked with a result indicator. Always check the batch identifier on the report.
How should the material be stored?
Keep the sealed lyophilised material dry and protected from light. A cool, dry place, refrigerator or freezer may be used according to the intended storage duration, compound-specific information and your laboratory’s validated procedure. Avoid repeated temperature cycling and moisture exposure. No universal shelf-life is stated unless it is supported by batch documentation.
Information reviewed: 29 August 2026.
Batch-specific analytical documentation
Independent analytical results are published for selected Havoc Labs products, vial sizes and batches. The result attached to one variation must not be treated as evidence for a different size or batch.
- Result available: a published report is available for the marked variation.
- Test pending: a sample has been submitted, but no completed result is being claimed.
- No indicator: no product-specific result is currently displayed for that variation.
Check the identifiers
Always match the compound, vial size and batch reference on the product to the corresponding laboratory record. Where the laboratory provides an independent verification facility, use it to confirm the report.
Browse published lab results →
Storage and stability
Storage requirements can vary by compound, physical form, intended storage duration and batch. Follow the lot-specific documentation and your laboratory’s validated procedure wherever these are available.
| Form |
Suggested storage |
Important note |
| Sealed lyophilised material |
Keep in a cool, dry place, refrigerated at 2–8°C or frozen, as appropriate for the compound and intended storage period. |
Keep sealed, dry and protected from direct light. Follow compound- and batch-specific documentation and avoid repeated temperature cycling. |
| Reconstituted solution |
Refrigerate at 2–8°C unless the applicable laboratory protocol specifies otherwise. |
Stability depends on the preparation conditions, solvent, concentration, container and handling. No universal storage period is claimed. |
No universal shelf-life is claimed
Do not assume a fixed expiry or prepared-solution storage period unless it is supported by relevant stability data or batch documentation. Where a lot-specific document gives different instructions, that document takes precedence.
Published research
The sources below concern cagrilintide (AM833 / NNC0174-0833) as investigated by their respective authors. They are provided for scientific context and do not establish the identity, purity, performance or suitability of any material sold on this page.
- Bailey RJ et al. AM833 Is a Novel Agonist of Calcitonin Family G Protein-Coupled Receptors: Pharmacological Comparison with Six Selective and Nonselective Agonists. Journal of Pharmacology and Experimental Therapeutics, 2021. View on PubMed ↗
- Lau DCW et al. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. The Lancet, 2021. View on PubMed ↗
- Enebo LB et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg for weight management. The Lancet, 2021. View on PubMed ↗
- PubChem. Cagrilintide compound record CID 171397054, containing reference identifiers and structural information. View compound record ↗
Literature is not batch evidence
Published findings relate to the materials, participants and conditions used by the cited researchers. Assess any available batch documentation separately.
